Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: With pre-symptomatic stages of Alzheimer's disease (AD) becoming the primary target for therapeutic intervention, there is an unmet need for practical biomarkers to facilitate the diagnosis of these early disease stages. MicroRNAs, small non-coding RNAs with a high stability in extracellular environments, are a promising source of accessible biomarkers. In this study we investigated the use of blood-based microRNAs as prognostic biomarkers for the development of dementia and diagnosis of AD.Methods: MicroRNAs were profiled via a genome-wide high-throughput platform in plasma from patients with mild cognitive impairment (MCI) and clinical AD. Identified candidate microRNAs were verified by individual RT-qPCR and a novel electrochemical detection system. Subjects were recruited as part of a longitudinal aging study and underwent annual clinical assessments and blood sampling.Findings: Let-7b and microRNA-206 were identified at elevated levels in MCI and dementia and AD, respectively. MicroRNA-206 displayed a strong correlation with cognitive decline and memory deficits. Longitudinal follow up over 5 years identified microRNA-206 increases preceding the onset of dementia. MiR-206 was also detected at increased concentrations in unprocessed plasma of AD and MCI subjects using a microfluidic device.Interpretation: While increased Let-7b levels in plasma may be used to identify patients with MCI, changes in plasma levels of microRNA-206 may be used to predict cognitive decline and progression towards dementia at an MCI stage. MicroRNA quantification via a microfluidic device could provide a practical cost-effective tool for stratification of patients with MCI according to risk of developing AD.Funding Statement: This work was supported by funding from the Health Research Board HRA-POR-2015-1243 to TE; Science Foundation Ireland (17/CDA/4708 to T.E, 18/FIP/3552 to ES and KA, and co-funded under the European Regional Development Fund and by FutureNeuro industry partners 16/RC/3948 to DCH) and funding from CIBERNED and the Spanish Ministry of Science (SAF2016-78603-R) to MM and MC. The Vallecas Project is supported by institutional grants from the Queen Sofia Foundation, CIEN Foundation and the Carlos III Institute of Health. Declaration of Interests: This work was supported by funding from the Health Research Board HRA-POR-2015-1243 to TE; Science Foundation Ireland (17/CDA/4708 to T.E, 18/FIP/3552 to ES and KA, and co395 funded under the European Regional Development Fund and by FutureNeuro industry partners 16/RC/3948 to DCH) and funding from CIBERNED and the Spanish Ministry of Science (SAF2016-78603-R) to MM and MC. The Vallecas Project is supported by institutional grants from the Queen Sofia Foundation, CIEN Foundation and the Carlos III Institute of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The other authors have declared no conflict of interest.Ethics Approval Statement: The project was approved by the Ethics Committee of the Carlos III Institute of Health. All participants provided written informed consent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“The advanced stages of AD, at which clinical trials are applied, are often cited as a major contributor to the serial failures of AD therapeutic trials [3,4].”
BackgroundPreclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“Consequently, the focus has now shifted to implementing therapies at earlier stages of the disease offering a better opportunity for effective treatment and greater retention of cognitive function [8].”
BackgroundTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“The advanced stages of AD, at which clinical trials are applied, are often cited as a major contributor to the serial failures of AD therapeutic trials [3,4].”
BackgroundCogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943
Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03135.x · Cited by 691
BDNF mechanisms in late LTP formation: A synthesis and breakdown
Panja, D., & Bramham, C. R. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.024 · Cited by 336
miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model
Lee, S., Chu, K., Jung, K., Kim, J. H., Huh, J., Yoon, H., Park, D., Lim, J., Kim, J., Jeon, D., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23588 · Cited by 326
Pre- and postsynaptic twists in BDNF secretion and action in synaptic plasticity.
Edelmann, E., Leßmann, V., & Brigadski, T. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.043 · Cited by 248
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease
Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., & Jahn, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126423 · Cited by 236
MicroRNAs in Neurodegenerative Diseases
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2017.04.002 · Cited by 168
Self-citationJimenez-Mateos, E. M., Arribas-Blazquez, M., Sanz-Rodriguez, A., Concannon, C., Olivos-Ore, L. A., Reschke, C. R., Mooney, C. M., Mooney, C., Lugara, E., Morgan, J., et al. (2015) · Scientific Reports · doi:10.1038/srep17486 · Cited by 103
Self-citationEarly diagnosis of Alzheimer's disease from elevated olfactory mucosal miR-206 level.
Moon, J., Lee, S.-T., Kong, I. G., Byun, J.-I., Sunwoo, J.-S., Shin, J.-W., Shim, J.-Y., Park, J.-H., Jeon, D., Jung, K.-H., et al. (2016) · Scientific Reports · doi:10.1038/srep20364 · Cited by 69
Cited by
Circulating Exosomal miRNA as Diagnostic Biomarkers of Neurodegenerative Diseases
Wang, L., & Zhang, L. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00053 · Cited by 164
MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers
Wei, W., Wang, Z.-Y., Ma, L.-N., Zhang, T.-T., Cao, Y., & Li, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00160 · Cited by 103
microRNAs as early biomarkers of Alzheimer’s disease: a synaptic perspective
Siedlecki-Wullich, D., Miñano-Molina, A. J., & Rodríguez-Álvarez, J. (2021) · Cells · doi:10.3390/cells10010113 · Cited by 76
Unveiling the Complex Role of Exosomes in Alzheimer’s Disease
Sun, M., & Chen, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466821 · Cited by 39
“[200] miR-103, miR-107 Plasma Downregulated The level of these miRNAs are downregulated in the plasma of AD patients and can distinguish AD patients from healthy controls.”
Background
Metadata
- Authors
- Kenny, A., McArdle, H., Calero, M., Rabano, A., Madden, S. F., Adamson, K., Forster, R., Spain, E., Prehn, J. H. M., Henshall, D. C., Medina, M., Jimenez-Mateos, E. M., & Engel, T.
- Venue
- SSRN Electronic Journal
- Publisher
- Elsevier BV
- Published
- 2019
- Volume
- 9
- Issue
- 11
- Pages
- 734-734
- ISSN
- 2218-273X (ISSN-L)
- 1556-5068
- OpenAlex
- W2989531900
- Cited by
- 71
- References
- 15
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.